MediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewedAmerican Journal of Endocannabinoid Medicine .- This is the largest peer reviewed published study of its kind on Fibromyalgia and cannabis, with over 800 patient assessments.
- Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
- The study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
The retrospective study was led by HMED and reviewed data from 805 patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and had a minimum of one follow-up assessment. The majority of patients (76.1%) reported using CBD oil, which aligns with the current practice guidelines for authorizing medical cannabis as an adjuvant therapy for managing chronic pain.
The primary findings from the present study include a significant reduction in all three scores measuring depression, anxiety, and illness severity between baseline and first follow-up.
- 75% of patients saw a decrease in their self-reported illness severity, which may include chronic pain, insomnia, and fatigue.
- Anxiety scores were improved in 22% of those patients reporting mild-moderate severity, and in 48% of patients reporting severe anxiety.
- 27% of patients reporting mild-medium depression noted a reduction in symptoms, while 48% of patients reporting severe depression showed a reduction in PHQ-9 score.
The validated study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety, and that additional, similar studies are recommended.
"Since 2017, Harvest Medicine's primary objective is to improve the quality of patients' lives by providing access to medical cannabis and offering the highest standard of medical care with a scientifically informed approach" commented
Details on the study can be viewed on
Summary of MediPharm Labs Clinical Projects
Researcher | Indication | Phase | Recent Milestone |
Treatment of post-surgical pain | Two | CTM delivered and Patient dosing | |
| Improving Pain Disability with
| Pilot | CTM Delivered and
|
Insomnia in depressive | Two | CTM Shipment in Q1 2023. Patient dosing | |
PK of single dose THC/CBD in | One | First patient dosed | |
University of | Chronic Headaches in | Two |
|
Harvest Medicine | Self-Reported Effects of Illness | Real | Peer reviewed and |
Harvest Medicine Clinic ( | Medical cannabis use impact | Real | Peer reviewed and |
In addition to institutionally led studies, the Company is also providing API and clinical trial material to various pharmaceutical companies for commercial projects involving cannabis-derived drugs. The timelines for both institutional and industry research are long by nature with positive outcomes uncertain.
Founded in 2015,
In 2021,
In 2023,
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, opportunities for future clinical research projects and the future supply to the global pharmaceutical industry, future marketable pharmaceutical products, and future Canadian and international commercial products that leverage MPL's unique Pharma expertise. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; the inability of
View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-publishes-study-investigating-medical-cannabis-impacts-on-anxiety-and-depression-outcomes-in-fibromyalgia-patients-301914834.html
SOURCE
© Canada Newswire, source